HIGH-FLOW NASAL CANNULA THERAPY AS AN ADJUVANT IN THE TREATMENT OF SEVERE SEPSIS. A Multicenter parallel-group randomized clinical trial. - OPTISEPSIS

Althaia Xarxa Assistencial Universitària de Manresa. Fundació Privada.0 个研究点目标入组 592 人开始时间: 2018年8月2日最近更新: 2019年1月7日

适应症

试验速览

暂无简介。

•Patients > 18 years, with diagnostic criteria of severe sepsis in the first 6 hours after admission to the Emergency Room defined as hypotension after hemodynamic resuscitation, initial lactate> 4, or persistence of organic dysfunction (oliguria <0.5 ml / kg / hour, cyanosis, lividities, altered consciousness
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 592
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•- Patients requiring immediate ventilatory support, both invasive and non-invasive, defined by severe hypoxemia (PaO2 / FiO2 <150), severe tachypnea (40x ') with signs of respiratory fatigue or low level of consciousness (Glasgow <8).
•- Patients with limited therapeutic effort or orders of non-CPR.
•- Patients not susceptible to treatment with OAF (facial trauma, tracheostomized, rejection of previous treatments with OAF).
•- Participation in other clinical trials that may affect survival.
•-Pregnant women.

发起方

Althaia Xarxa Assistencial Universitària de Manresa. Fundació Privada.